Anti Tumor Necrosis Factor-a Monoclonal Antibody (Infliximab) Therapy in Patients with Inflammatory Bowel Disease (IBD): Applications and Side Effects

Publisher： Bentham Science Publishers

ISSN： 1567-2697

Source： Drug Design Reviews - Online, Vol.1, Iss.2, 2004-01, pp. : 111-117

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Tumor Necrosis Factor Blockade for Treatment of Inflammatory Bowel Disease: Efficacy and Safety

By  

Current Molecular Pharmacology, Vol. 3, Iss. 3, 2010-11 ,pp. : 145-152

Bentham Science Publishers

Access to resources Recommend Favorite

Pharmacogenomics of Response to Anti-Tumor Necrosis Factor Therapy in Patients with Crohn’s Disease

By Shetty A.   Forbes A.  

American Journal of PharmacoGenomics, Vol. 2, Iss. 4, 2002-01 ,pp. : 215-221

Adis International

Access to resources Recommend Favorite

Infliximab Therapy in Children and Adolescents with Inflammatory Bowel Disease

By Veres Gabor  

Drugs, Vol. 67, Iss. 12, 2007-01 ,pp. : 1703-1723

Adis International

Access to resources Recommend Favorite

Infliximab use appears to increase the risk of heart disorders, including arrhythmias, in children with inflammatory bowel disease (IBD)

By  

Reactions Weekly, Vol. 1, Iss. 1117, 2006-01 ,pp. : 5-5

Adis International

Access to resources Recommend Favorite

Infliximab use appears to increase the risk of heart disorders, including arrhythmias, in children with inflammatory bowel disease (IBD)

By  

Inpharma, Vol. 1, Iss. 1553, 2006-01 ,pp. : 21-21

Adis International

Access to resources Recommend Favorite